Cyclo Therapeutics, Inc. (CYTH) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 16, 2022 8:05 AM EDTOn track to commence Phase 2 study of Trappsol® Cyclo for the treatment of Alzheimers Disease before year end
Continued execution on advancement of lead development program evaluating Trappsol® Cyclo for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC)
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq:... More
